TXG - 10X Genomics Inc Stock Price, Fair Value and News

25.97USD-0.42 (-1.59%)Market Closed

Market Summary

USD25.97-0.42

Market Closed

-1.59%

TXG Alerts

Losses in recent quarter

TXG Stock Price

View Fullscreen

TXG RSI Chart

TXG Valuation

Market Cap

3.2B

Price/Earnings (Trailing)

-11.92

Price/Sales (Trailing)

5.04

EV/EBITDA

-12.78

Price/Free Cashflow

-42.72

TXG Price/Sales (Trailing)

TXG Profitability

Operating Margin

64.57%

EBT Margin

-41.08%

Return on Equity

-36.77%

Return on Assets

-28.64%

Free Cashflow Yield

-2.34%

TXG Fundamentals

TXG Revenue

Revenue (TTM)

625.4M

Rev. Growth (Yr)

5.01%

Rev. Growth (Qtr)

-23.36%

TXG Earnings

Earnings (TTM)

-264.3M

Earnings Growth (Yr)

-18.13%

Earnings Growth (Qtr)

-22.46%

Breaking Down TXG Revenue

52 Week Range

25.8763.57

(Low)(High)

Last 7 days

0.3%

Last 30 days

-29.4%

Last 90 days

-46.7%

Trailing 12 Months

-51.5%

How does TXG drawdown profile look like?

TXG Financial Health

Current Ratio

5.22

TXG Investor Care

Shares Dilution (1Y)

3.26%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	625.4M	0	0	0
2023	536.2M	568.4M	591.0M	618.7M
2022	499.2M	497.9M	503.7M	516.4M
2021	332.8M	405.7M	459.2M	490.5M
2020	264.2M	251.3M	261.9M	298.8M
2019	172.5M	196.6M	221.2M	245.9M
2018	89.9M	108.7M	127.5M	146.3M
2017	0	0	0	71.1M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of 10X Genomics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 21, 2024	mcanear justin j.	acquired	-	-	53,312	chief financial officer
Mar 21, 2024	saxonov serge	acquired	-	-	88,854	chief executive officer
Mar 21, 2024	hindson benjamin j.	acquired	-	-	71,083	see remarks
Mar 14, 2024	saxonov serge	gifted	-	-	-1,086	chief executive officer
Mar 04, 2024	saxonov serge	sold	-205,021	43.9959	-4,660	chief executive officer
Feb 22, 2024	hindson benjamin j.	sold	-121,098	46.3443	-2,613	see remarks
Feb 22, 2024	mcanear justin j.	sold	-86,432	46.3443	-1,865	chief financial officer
Feb 22, 2024	saxonov serge	sold	-130,737	46.3443	-2,821	chief executive officer
Feb 15, 2024	saxonov serge	sold	-244,332	48.8664	-5,000	chief executive officer
Feb 09, 2024	saxonov serge	sold	-49,530	49.5301	-1,000	chief executive officer

Which funds bought or sold TXG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	NORTH STAR ASSET MANAGEMENT INC	added	7.35	-637,096	1,637,620	0.08%
May 08, 2024	Interchange Capital Partners, LLC	new	-	207,580	207,580	0.14%
May 08, 2024	Entropy Technologies, LP	new	-	993,494	993,494	0.11%
May 08, 2024	Russell Investments Group, Ltd.	added	1,136	4,833,140	5,496,040	0.01%
May 08, 2024	TD Asset Management Inc	added	37.94	-1,153,140	14,245,000	0.01%
May 08, 2024	STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM	added	3.88	179,229	5,200,970	0.01%
May 08, 2024	US BANCORP \DE\	reduced	-8.68	-329,898	521,366	-%
May 08, 2024	Bell Investment Advisors, Inc	reduced	-36.36	-2,117	1,577	-%
May 08, 2024	KBC Group NV	added	25.57	-17,000	87,000	-%
May 08, 2024	Bleakley Financial Group, LLC	sold off	-100	-234,416	-	-%

Are Funds Buying or Selling TXG?

Are funds buying TXG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TXG

No. of Funds

TXG Alerts

Losses in recent quarter

Unveiling 10X Genomics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	8.65%	9,011,332	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 31, 2024	blackrock inc.	5.5%	5,705,051	SC 13G/A
Jan 29, 2024	baillie gifford & co	7.60%	7,919,976	SC 13G/A
Dec 08, 2023	morgan stanley	3.5%	3,630,398	SC 13G/A
Jul 10, 2023	morgan stanley	5.2%	5,139,461	SC 13G/A
Jul 10, 2023	fmr llc	-	0	SC 13G/A
Feb 14, 2023	venrock associates vi, l.p.	4.9%	4,828,247	SC 13G/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Feb 09, 2023	vanguard group inc	8.81%	8,420,011	SC 13G/A

Recent SEC filings of 10X Genomics Inc

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	10-Q	Quarterly Report
Apr 30, 2024	8-K	Current Report
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Apr 12, 2024	PRE 14A	PRE 14A
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 18, 2024	4	Insider Trading
Mar 06, 2024	4	Insider Trading

Peers (Alternatives to 10X Genomics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
UNH	466.7B	379.5B	10.30%	3.46%	30.38	1.23	12.96%	-25.81%
CI	99.7B	206.0B	-1.82%	33.22%	25.87	0.48	12.55%	-43.95%
HCA	84.3B	66.7B	-2.18%	15.50%	15.4	1.26	9.59%	-4.59%
CVS	69.9B	360.9B	-24.11%	-20.14%	9.54	0.19	9.07%	78.49%
CNC	41.4B	155.5B	6.79%	16.14%	15.15	0.27	6.34%	84.42%
DVA	12.1B	12.3B	2.88%	38.95%	14.83	0.98	5.77%	58.74%
UHS	11.9B	14.7B	3.23%	25.09%	14.57	0.81	7.99%	19.23%
MID-CAP
CHE	8.7B	2.3B	-8.08%	4.15%	30.63	3.79	5.96%	18.29%
ACHC	6.5B	3.0B	-7.64%	1.03%	-578.78	2.19	10.92%	-104.06%
AMN	2.3B	3.5B	0.76%	-34.62%	16.07	0.66	-27.67%	-62.43%
AMEH	2.2B	1.5B	-8.15%	19.83%	35.09	1.51	19.34%	40.15%
SMALL-CAP
ADUS	1.7B	1.1B	7.65%	29.55%	26.45	1.6	11.45%	30.74%
BKD	1.4B	3.0B	4.67%	77.04%	-7.95	0.45	4.98%	4.88%
BEAT	52.9M	-	-5.61%	-9.82%	-3.5	-	-	-1.05%
AMS	19.9M	21.3M	3.03%	6.99%	37.29	0.93	8.00%	-62.25%

10X Genomics Inc News

Latest updates

10X Genomics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-23.4%	141,006,000	183,979,000	153,644,000	146,819,000	134,285,000	156,232,000	131,072,000	114,609,000	114,496,000	143,530,000	125,297,000	115,842,000	105,821,000	112,218,000	71,817,000	42,905,000	71,905,000	75,289,000	61,207,000	55,819,000	53,578,000
Cost Of Revenue	-29.5%	48,092,000	68,197,000	58,115,000	47,207,000	35,895,000	36,827,000	30,377,000	27,704,000	25,478,000	27,598,000	24,518,000	4,915,000	17,060,000	18,897,000	14,411,000	10,052,000	15,108,000	16,582,000	15,480,000	15,006,000	13,965,000
Gross Profit	-19.8%	92,914,000	115,782,000	95,529,000	99,612,000	98,390,000	119,405,000	100,695,000	86,905,000	89,018,000	115,932,000	100,779,000	110,927,000	88,761,000	93,321,000	57,406,000	32,853,000	56,797,000	58,707,000	45,727,000	40,813,000	39,613,000
Operating Expenses	-9.7%	154,412,000	170,970,000	190,324,000	162,970,000	150,378,000	142,501,000	140,691,000	150,022,000	130,753,000	131,762,000	116,658,000	121,255,000	98,977,000	502,904,000	122,661,000	72,273,000	76,681,000	66,787,000	54,823,000	51,175,000	42,648,000
S&GA Expenses	-0.4%	85,774,000	86,125,000	82,415,000	91,510,000	83,280,000	78,887,000	73,401,000	79,337,000	66,675,000	69,877,000	62,076,000	68,703,000	56,904,000	55,974,000	51,549,000	44,416,000	50,387,000	38,756,000	32,614,000	32,571,000	26,893,000
EBITDA Margin	-1.5%	-0.35	-0.34	-0.31	-0.24	-0.27	-0.26	-0.27	-0.23	-0.12	-0.06	-0.93	-1.17	-1.53	-1.74	-0.45	-0.25	-0.14	-0.08	-0.48	-0.54	-0.62
Interest Expenses	-87.5%	1,000	8,000	1,000	5,000	19,000	125,000	114,000	109,000	128,000	217,000	219,000	209,000	221,000	317,000	397,000	306,000	662,000	992,000	708,000	695,000	684,000
Income Taxes	-8.8%	2,146,000	2,354,000	1,242,000	1,647,000	1,093,000	804,000	1,879,000	627,000	719,000	2,456,000	523,000	1,094,000	435,000	6,949,000	585,000	422,000	300,000	113,000	8,000	68,000	34,000
Earnings Before Taxes	-24.0%	-57,803,000	-46,598,000	-91,744,000	-60,767,000	-49,654,000	-16,411,000	-40,035,000	-63,831,000	-41,694,000	-15,993,000	-16,648,000	-9,958,000	-11,116,000	-408,623,000	-65,263,000	-39,745,000	-20,845,000	-7,026,000	-9,595,000	-10,810,000	-3,602,000
EBT Margin	-2.2%	-0.41	-0.40	-0.37	-0.29	-0.32	-0.31	-0.32	-0.28	-0.17	-0.11	-0.97	-1.22	-1.58	-1.79	-0.51	-0.31	-0.18	-0.13	-0.51	-0.57	-0.65
Net Income	-22.5%	-59,949,000	-48,952,000	-92,986,000	-62,414,000	-50,747,000	-17,215,000	-41,914,000	-64,458,000	-42,413,000	-18,449,000	-17,171,000	-11,052,000	-11,551,000	-415,573,000	-65,848,000	-40,167,000	-21,143,000	-7,134,000	-9,603,000	-10,878,000	-3,636,000
Net Income Margin	-2.5%	-0.42	-0.41	-0.38	-0.30	-0.33	-0.32	-0.33	-0.29	-0.18	-0.12	-0.99	-1.24	-1.60	-1.82	-0.51	-0.31	-0.18	-0.13	-0.45	-0.54	-0.58
Free Cashflow	-183.5%	-18,635,000	22,308,000	-40,540,000	-36,882,000	-8,684,000	-26,011,000	-46,136,000	-44,182,000	-48,938,000	-21,813,000	-46,443,000	-11,448,000	-42,947,000	-151,514,000	-56,138,000	-36,257,000	-10,655,000	144,000	848,000	-9,058,000	-49,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-4.4%	923	965	949	990	1,014	1,029	996	1,002	1,003	1,019	991	978	954	929	1,043	583	610	606	573	124
Current Assets	-4.9%	567	596	562	583	602	635	629	666	697	748	744	757	746	774	900	452	430	481	474	106
Cash Equivalents	-1.0%	356	359	315	331	340	227	242	282	320	596	609	649	644	689	834	404	432	476	477	70.00
Inventory	12.9%	83.00	74.00	81.00	84.00	82.00	82.00	79.00	71.00	64.00	60.00	51.00	44.00	39.00	30.00	25.00	22.00	19.00	15.00	13.00	9.00
Net PPE	-3.6%	269	280	285	285	292	289	258	223	190	169	143	122	107	73.00	65.00	56.00	52.00	49.00	47.00	11.00
Goodwill	0%	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	5.00	-	-	-	-	-	-
Liabilities	-8.9%	204	224	203	196	212	223	220	218	197	201	190	193	202	190	217	192	201	186	151	101
Current Liabilities	-14.5%	109	127	105	98.00	112	131	127	118	94.00	110	100	113	121	118	146	122	59.00	63.00	48.00	32.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	22.00	25.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	10.00	7.00	4.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	20.00	22.00	25.00
Shareholder's Equity	-3.0%	719	741	745	793	802	806	776	784	807	818	800	785	752	739	825	391	409	420	421	-
Retained Earnings	-4.7%	-1,344	-1,284	-1,235	-1,142	-1,080	-1,029	-1,012	-970	-905	-863	-844	-827	-816	-805	-389	-323	-283	-262	-255	-231
Additional Paid-In Capital	1.9%	2,064	2,026	1,981	1,937	1,884	1,839	1,793	1,758	1,715	1,681	1,645	1,612	1,569	1,544	1,215	715	693	682	677	11.00
Accumulated Depreciation	6.7%	110	103	94.00	86.00	-	69.00	-	-	-	49.00	44.00	39.00	35.00	31.00	-	-	-	19.00	-	14.00
Shares Outstanding	0.3%	119	119	118	117	116	115	114	114	113	110	110	110	109	101	101	98.00	97.00	39.00	29.00	13.00
Float	-	-	-	-	5,700	-	-	-	4,500	-	-	-	18,700	-	-	-	7,300	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-161.0%	-15,725	25,758	-25,304	-11,526	-4,125	13,723	-9,564	-16,963	-20,802	5,805	-26,216	3,120	-4,082	-130,175	-55,629	-29,518	-2,576	6,700	14,526	4,083	9,318
Share Based Compensation	-7.2%	36,129	38,918	40,235	45,696	42,101	40,974	33,514	36,313	26,047	26,904	25,950	26,932	16,176	14,269	13,784	13,855	6,718	5,075	3,874	3,025	1,359
Cashflow From Investing	-18.8%	10,632	13,098	4,900	-4,462	119,956	-33,172	-32,630	-27,527	-257,558	-27,618	-20,227	-14,568	-44,316	-22,266	-1,310	-6,739	-8,079	-6,581	-13,678	-13,141	-9,367
Cashflow From Financing	-70.8%	1,638	5,613	4,374	7,096	-3,414	5,001	2,039	6,360	2,417	8,903	6,683	16,193	3,518	7,706	486,968	8,051	-33,819	-1,107	415,638	-864	923

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

TXG Income Statement

2024-03-31

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 141,006	$ 134,285
Cost of revenue	48,092	35,895
Gross profit	92,914	98,390
Operating expenses:
Research and development	68,638	67,098
Selling, general and administrative	85,774	83,280
Total operating expenses	154,412	150,378
Loss from operations	(61,498)	(51,988)
Other income (expense):
Interest income	4,736	3,869
Interest expense	(1)	(19)
Other expense, net	(1,040)	(1,516)
Total other income	3,695	2,334
Loss before provision for income taxes	(57,803)	(49,654)
Provision for income taxes	2,146	1,093
Net loss	$ (59,949)	$ (50,747)
Net loss per share, basic (in dollars per share)	$ (0.50)	$ (0.44)
Net loss per share, diluted (in dollars per share)	$ (0.50)	$ (0.44)
Weighted-average shares of common stock used in computing net loss per share, basic (in shares)	119,394,180	115,619,869
Weighted-average shares of common stock used in computing net loss per share, diluted (in shares)	119,394,180	115,619,869

TXG Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 355,781	$ 359,284
Marketable securities	16,033	29,411
Accounts receivable, net	91,305	114,832
Inventory	83,189	73,706
Prepaid expenses and other current assets	20,785	18,789
Total current assets	567,093	596,022
Property and equipment, net	269,486	279,571
Operating lease right-of-use assets	62,850	65,361
Goodwill	4,511	4,511
Intangible assets, net	16,129	16,616
Other noncurrent assets	2,844	3,062
Total assets	922,913	965,143
Current liabilities:
Accounts payable	20,216	15,738
Accrued compensation and related benefits	20,670	30,105
Accrued expenses and other current liabilities	42,424	56,648
Deferred revenue	14,296	13,150
Operating lease liabilities	11,127	11,521
Total current liabilities	108,733	127,162
Operating lease liabilities, noncurrent	81,049	83,849
Deferred revenue, noncurrent	9,787	8,814
Other noncurrent liabilities	4,510	4,275
Total liabilities	204,079	224,100
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock	0	0
Common stock	2	2
Additional paid-in capital	2,063,657	2,025,890
Accumulated deficit	(1,344,369)	(1,284,420)
Accumulated other comprehensive loss	(456)	(429)
Total stockholders’ equity	718,834	741,043
Total liabilities and stockholders’ equity	$ 922,913	$ 965,143

About 10X Genomics Inc

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

CEO	Dr. Serge Saxonov Ph.D.
WEBSITE	10xgenomics.com
INDUSTRY	Healthcare Plans
EMPLOYEES	1243

10X Genomics Inc Frequently Asked Questions

What is the ticker symbol for 10X Genomics Inc? What does TXG stand for in stocks?

TXG is the stock ticker symbol of 10X Genomics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 10X Genomics Inc (TXG)?

As of Thu May 09 2024, market cap of 10X Genomics Inc is 3.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers.

What is the fair value of TXG stock?

You can check TXG's fair value in chart for subscribers. The fair value of 10X Genomics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 10X Genomics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TXG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 10X Genomics Inc a good stock to buy?

The fair value guage provides a quick view whether TXG is over valued or under valued. Whether 10X Genomics Inc is cheap or expensive depends on the assumptions which impact 10X Genomics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TXG.

What is 10X Genomics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, TXG's PE ratio (Price to Earnings) is -11.92 and Price to Sales (PS) ratio is 5.04. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TXG PE ratio will change depending on the future growth rate expectations of investors.